ReviewEnvironmental health perspectives2025
Systematic Evidence Map for the Per- and Polyfluoroalkyl Substances (PFAS) Universe.
Review in Environmental health perspectives, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Prenatal Exposure to PFOA Induces Ovarian Function Impairment via the Disruption of the PPARγ/ANGPTL4 Pathway.Environment & health (Washington, D.C.) · 2026Article
- PFAS Toxicity: What's True, What's Not, and What Really Matters.Environmental science & technology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
backgroundPer- and polyfluoroalkyl substances (PFAS) are a research priority for the U.S. Environmental Protection Agency (EPA). Because PFAS include thousands of structurally diverse chemicals, there is a pressing need for identifying what data are available to assess the human health hazard of these compounds.
objectivesWe used systematic evidence map (SEM) methods to summarize the available epidemiological and mammalian bioassay evidence for ∿14,735 chemicals identified as PFAS by EPA's Center for Computational Toxicology and Exposure (CCTE). This work is a continuation of our previous 2022 and 2024 SEMs that inventoried evidence on a separate set of ∿500 PFAS. The Comprehensive PFAS Dashboard includes evidence identified from our past SEMs and completed EPA assessments.
methodsWe conducted literature searches from peer-reviewed and gray literature sources to identify, screen, and inventory mammalian bioassay and epidemiological literature. A combination of manual review and machine learning software were utilized. A diverse array of potentially relevant supplemental content was also tracked, including mechanistic data, exposure-only studies, and studies informing chemical toxicokinetics and clearance. For each study meeting predefined population, exposure, comparator, and outcome (PECO) criteria, experimental design details and health endpoints evaluated were summarized in interactive web-based literature inventory visuals. Epidemiology studies and animal bioassay studies with ≥21-day exposure duration or reproductive/developmental study design proceeded to undergo a study evaluation for risk of bias and sensitivity, as well as detailed extraction of health endpoint data. Underlying data are publicly available and can be downloaded.
resultsScientific database searches retrieved 152,205 references. After full-text screening, there were 347 mammalian bioassay and 44 epidemiological studies that met PECO criteria. The mammalian bioassay and epidemiological evidence assessed 99 and 30 individual PFAS, respectively (n = 18 PFAS with both). The epidemiological evidence assessed 15 health systems and the mammalian bioassay evidence assessed 16 health systems. DISCUSSION: Results from our 2022 and 2024 SEMs and completed EPA assessments are compiled into Comprehensive PFAS Dashboard. This dashboard is a resource for better understanding the currently available PFAS human health hazard data. It can be used as a tool for researchers and regulators interested in PFAS data gaps and research needs. Across all the data sources compiled into the Comprehensive PFAS Dashboard, only 1.4% (214/14,735) of PFAS had any mammalian bioassay or epidemiological data available. The vast majority of PFAS lack publicly available information about the potential human health effects of exposure to these chemicals.. https://doi.org/10.1289/EHP16952.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.